The Federal Trade Commission is requesting public comment on a wide range of pharmacy benefit manager business activities including contract terms, rebates, fees, pricing policies, steering methods, conflicts of interest, and consolidation and how those practices impact patients, physicians, employers, and independent and chain pharmacies.
The request for information “will enable agency staff to study a wide array of PBM business practices and issues and...







